Global COVID-19 Therapeutics Market

Report ID : 1184 | Published : 2021-08-27 | Pages: 160 | Format: PDF/EXCEL

The increasing outbreak of covid-19 is increasing the demand for coronavirus vaccines or therapies, which will result in the expansion of the COVID-19 therapeutics market during the forecast period. According to the World Health Organization (WHO), globally, 175,847,347 confirmed cases of COVID-19, including 3,807,276 deaths, were reported to WHO as of 15 June 2021. Covid-19 cases are increasing day by day, and there is no officially approved drug for COVID-19. Many countries are facing a shortage of drugs likely to offer growth opportunities for pharmaceutical drug manufacturers. Leading market players are also developing innovative and efficient covid-19 drug therapies, resulting in overall market growth. 

Major factors responsible for the growth of the COVID 19 therapeutic market are the fast adoption of advanced technologies, the growing number of corona patients, increasing healthcare expenditures, rising awareness about coronavirus, and increasing efforts by the pharmaceutical companies to develop covid-19 therapeutic drugs. For instance, Eli Lilly and Company is donating COVID-19 therapies to Direct Relief, enabling the humanitarian organization to provide COVID-19 treatments at no cost to low- and lower-middle-income countries most heavily impacted by the pandemic. Furthermore, increasing research investments for the R&D of covid-19 therapeutic drugs is anticipated to drive market growth in the future. However, the high cost required to validate therapies, and long-term clinical trials limit the COVID-19 therapeutics market growth.

The COVID-19 therapeutics market can be segmented on Infection Type, Drug Class, and Region. By Infection Type, the market can be divided into HCoV-229E, HCoV-OC43, SARS-CoV, New Haven CoV, HKU1-CoV, MERS-CoV, and Other Infection Types. SARS-CoV segment is expected to dominate the market as this virus is the main reason for the covid-19 outbreak. The market can be segmented into Monoclonal Antibodies, Antiviral, Anticoagulant, Glucocorticoid, Nitric oxide, and Other Drug Class in terms of Drug Class. The monoclonal Antibodies segment has dominated the COVID-19 therapeutics market. Regionally, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America is expected to dominate the COVID-19 therapeutics market in the coming future.

Some of the key Players of COVID-19 therapeutics market are Atea Pharmaceuticals, Inc., CytoDyn, Celltrion, Eli Lilly and Company, NRX Pharmaceuticals, Shanghai Junshi Biosciences Co., Ltd., Veru Inc., Humanigen, Inc., Catalent, Inc., Cipla Limited, Molecular Partners AG, Merck, Novartis International AG, Regeneron Pharmaceuticals, Inc., Vir Biotechnology, Revive Therapeutics Ltd., Brii Biosciences Limited, GlaxoSmithKline plc, APEIRON Biologics AG, Bristol Myers Squibb, Janssen Pharmaceuticals, Trevena Inc, Ono Pharmaceutical Co., Ltd., Constant Therapeutics LLC, Amarin Corporation plc, FUJIFILM Toyama Chemical Co., Ltd., NeuroBo Pharmaceuticals, Inc., Innovation Pharmaceuticals Inc., Bellerophon Therapeutics, Sorrento Therapeutics, PhaseBio, Pfizer, Takeda, BioAegis Therapeutics, Roivant Sciences, AI Therapeutics, Inc., Celltex Therapeutics, Blade Therapeutics, Marinomed Biotech AG, Synairgen, SAb Biotherapeutics, Romark Laboratories, L.C., Kiniksa Pharmaceuticals, UNION therapeutics A/S, Fulcrum Therapeutics, and Other Prominent Players.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global COVID-19 Therapeutics Market Snapshot

Chapter 4. Global COVID-19 Therapeutics Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

4.9. Clinical Trial Analysis/Pipeline Analysis 2021

Chapter 5. Market Segmentation 2: By Drug Class Estimates & Trend Analysis

5.1. By Drug Class & Market Share, 2020 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Drug Class:

5.2.1. Monoclonal Antibodies

5.2.2. Antiviral

5.2.3. Anticoagulant

5.2.4. Glucocorticoid

5.2.5. Nitric oxide

5.2.6. Other Drug Class

Chapter 6. Market Segmentation 3: By Infection Type Estimates & Trend Analysis

6.1. By Infection Type & Market Share, 2020& 2030

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Infection Type:

6.2.1. HCoV-229E

6.2.2. HCoV-OC43

6.2.3. SARS-CoV

6.2.4. New Haven CoV

6.2.5. HKU1-CoV

6.2.6. MERS-CoV

6.2.7. Other Infection Types

Chapter 7. COVID-19 Therapeutics Market Segmentation 5: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America COVID-19 Therapeutics Market revenue (US$ Million) estimates and forecasts By Drug Class, 2020-2030

7.1.2. North America COVID-19 Therapeutics Market revenue (US$ Million) estimates and forecasts By Infection Type, 2020-2030

7.1.3. North America COVID-19 Therapeutics Market revenue (US$ Million) estimates and forecasts by country, 2020-2030

7.2. Europe

7.2.1. Europe COVID-19 Therapeutics Market revenue (US$ Million) By Drug Class, 2020-2030

7.2.2. Europe COVID-19 Therapeutics Market revenue (US$ Million) By Infection Type, 2020-2030

7.2.3. Europe COVID-19 Therapeutics Market revenue (US$ Million) by country, 2020-2030

7.3. Asia Pacific

7.3.1. Asia Pacific COVID-19 Therapeutics Market revenue (US$ Million) By Drug Class, 2020-2030

7.3.2. Asia Pacific COVID-19 Therapeutics Market revenue (US$ Million) By Infection Type, 2020-2030

7.3.3. Asia Pacific COVID-19 Therapeutics Market revenue (US$ Million) by country, 2020-2030

7.4. Latin America

7.4.1. Latin America COVID-19 Therapeutics Market revenue (US$ Million) By Drug Class, 2020-2030

7.4.2. Latin America COVID-19 Therapeutics Market revenue (US$ Million) By Infection Type, 2020-2030

7.4.3. Latin America COVID-19 Therapeutics Market revenue (US$ Million) by country, (US$ Million) 2020-2030

7.5. Middle East & Africa

7.5.1. Middle East & Africa COVID-19 Therapeutics Market revenue (US$ Million) By Drug Class, 2020-2030

7.5.2. Middle East & Africa COVID-19 Therapeutics Market revenue (US$ Million) By Infection Type, 2020-2030

7.5.3. Middle East & Africa COVID-19 Therapeutics Market revenue (US$ Million) by country, 2020-2030

  Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles

 8.2.1. Atea Pharmaceuticals, Inc.

8.2.2. CytoDyn

8.2.3. Celltrion

8.2.4. Eli Lilly and Company

8.2.5. NRX Pharmaceuticals

8.2.6. Shanghai Junshi Biosciences Co., Ltd.

8.2.7. Veru Inc.

8.2.8. Humanigen, Inc.

8.2.9. Catalent, Inc.

8.2.10. Cipla Limited

8.2.11. Molecular Partners AG

8.2.12. Merck

8.2.13. Novartis International AG

8.2.14. Regeneron Pharmaceuticals, Inc.

8.2.15. Vir Biotechnology

8.2.16. Revive Therapeutics Ltd.

8.2.17. Brii Biosciences Limited

8.2.18. GlaxoSmithKline plc

8.2.19. APEIRON Biologics AG

8.2.20. Bristol Myers Squibb

8.2.21. Janssen Pharmaceuticals

8.2.22. Trevena Inc

8.2.23. Ono Pharmaceutical Co., Ltd.

8.2.24. Constant Therapeutics LLC

8.2.25. Amarin Corporation plc

8.2.26. FUJIFILM Toyama Chemical Co., Ltd.

8.2.27. NeuroBo Pharmaceuticals, Inc.

8.2.28. Innovation Pharmaceuticals Inc.

8.2.29. Bellerophon Therapeutics

8.2.30. Sorrento Therapeutics

8.2.31. PhaseBio

8.2.32. Pfizer

8.2.33. Takeda

8.2.34. BioAegis Therapeutics

8.2.35. Roivant Sciences

8.2.36. AI Therapeutics, Inc.

8.2.37. Celltex Therapeutics

8.2.38. Blade Therapeutics

8.2.39. Marinomed Biotech AG

8.2.40. Synairgen

8.2.41. SAb Biotherapeutics

8.2.42. Romark Laboratories, L.C.

8.2.43. Kiniksa Pharmaceuticals

8.2.44. UNION therapeutics A/S

8.2.45. Fulcrum Therapeutics

8.2.46. Other Prominent Players

Global COVID-19 therapeutics Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on Infection Type

  • HCoV-229E
  • HCoV-OC43
  • SARS-CoV
  • New Haven CoV
  • HKU1-CoV
  • MERS-CoV
  • Other Infection Types

Global COVID-19 therapeutics Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on Drug Class

  • Monoclonal Antibodies
  • Antiviral
  • Anticoagulant
  • Glucocorticoid
  • Nitric oxide
  • Other Drug Class

Global COVID-19 therapeutics Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

North America COVID-19 therapeutics market revenue (US$ Million) by Country, 2020 to 2030

  • U.S.
  • Canada

Europe COVID-19 therapeutics market revenue (US$ Million) by Country, 2020 to 2030

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific COVID-19 therapeutics market revenue (US$ Million) by Country, 2020 to 2030

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America COVID-19 therapeutics market revenue (US$ Million) by Country, 2020 to 2030

  • Brazil
  • Mexico
  • Rest of Latin America

The Middle East & Africa COVID-19 therapeutics market revenue (US$ Million) by Country, 2020 to 2030

  • GCC Countries
  • South Africa
  • Rest of the Middle East & Africa

 Competitive Landscape

  • Company Overview
  • Financial Performance
  • Key Development
  • Latest Strategic Developments

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

 

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

 

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

 

Need Complete Report ?
Our Clients